Metraipolis › archive › dc_427afe70a22f

Polatuzumab vedotin-R-CHP used for high-risk EBV-negative DLBCL-type post-transplant lymphoproliferative disorder in a long-term kidney transplant recipient:… — Europe PMC PMID:41584571

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41584571
DOI
10.3389/fonc.2025.1673495
License (as archived)
solo-consultazione
Archived
2026-11-06T23:38:05.313Z
SHA-256 of the archived text
63416dddeda612523ae659a903f09d76d50f776280195c405e8c504b3a4a4977
Stable URL of this page
https://metraipolis.com/documento/dc_427afe70a22f

How to cite

Polatuzumab vedotin-R-CHP used for high-risk EBV-negative DLBCL-type post-transplant lymphoproliferative disorder in a long-term kidney transplant recipient:… — Europe PMC PMID:41584571 — Europe PMC (en), https://europepmc.org/article/MED/41584571 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_427afe70a22f (Metraipolis archive dc_427afe70a22f, sha256 63416dddeda612523ae659a903f09d76d50f776280195c405e8c504b3a4a4977)
BibTeX
@misc{dc427afe70a22f,
  title = {Polatuzumab vedotin-R-CHP used for high-risk EBV-negative DLBCL-type post-transplant lymphoproliferative disorder in a long-term kidney transplant recipient:… — Europe PMC PMID:41584571},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41584571},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_427afe70a22f; sha256 63416dddeda612523ae659a903f09d76d50f776280195c405e8c504b3a4a4977},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41584571. Agents can read the archived copy with the MCP tool read_document.